Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer
Stopped early · Phase 1/Phase 2
Conditions studied: Breast Cancer
In brief
The majority pf breast cancers present as ER-positive, many of which are able to be targeted with multiple hormonal therapies. Altering ER-negative tumors to increase ER expression has the potential to benefit patients by making hormonal therapies a therapeutic option and possibly improving their overall prognosis.
Key facts
- Study ID
- NCT00726180
- Run by
- University of Michigan Rogel Cancer Center
- People needed
- 1
- Starts
- 2008-07-01
- Expected to finish
- 2010-10-01
- Last updated by the study team
- 2013-10-15
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Women who have Her-2 positive and ER- negative or ER-low breast cancer that has not metastasized, or spread to other parts of the body, are eligible for the study.
- Participants must have had either a core biopsy or incisional biopsy of their breast cancer, but not yet had definitive breast surgery, including lumpectomy or mastectomy.
- Participants may not have had a BRCA mutation found on genetic testing.
- Participants should have not yet received treatment for their breast cancer, including:
- chemotherapy,
- hormonal therapy,
- trastuzumab.
Where it is running
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.